Medical Patent News

RSS

VIVUS granted three additional patents for Qnexa

VIVUS, Inc. today announced the issuance of three additional patents by the U.S. Patent and Trademark Office (USPTO) covering Qnexa, an investigational new drug candidate for the treatment of obesity. The three new patents are the second, third, and fourth patents to be granted in a series of patent applications VIVUS has filed that are directed to the Qnexa product and methods of using Qnexa in various therapeutic applications.

8 Mar 2010

USPTO issues non-final Actions Closing Prosecution for 6,833,252 and 7,214,536 patents

Precision BioSciences, Inc., today announced that the United States Patent and Trademark Office (PTO) has issued non-final Actions Closing Prosecution in the reexamination proceedings for U.S. Pat. Nos. 6,833,252 (“the ‘252 patent”) and 7,214,536 (“the ‘536 patent”) that are owned by the Institut Pasteur and the Universite Pierre et Marie Cure (UPMC), and licensed to Cellectis, SA (ALCLS). For the second time, the PTO has rejected all claims under consideration as lacking novelty and/or as obvious in view of a variety of references, including many that were not provided to the patent examiners during prosecution by the patent applicants.

8 Mar 2010

Sandata Technologies, Infocrossing reach agreement over patent infringement lawsuit

Sandata Technologies, Inc., a leading nationwide provider of information technology solutions to the home healthcare and social services communities, and Infocrossing, Inc. today announced the settlement of the patent infringement lawsuit between the two companies.

6 Mar 2010

Retractable Technologies v. OMI litigation: Court delivers final judgment and permanent injunction

Retractable Technologies, Inc., a leading maker of safety needle devices, announced that a final judgment and permanent injunction were entered March 4, 2010 in the litigation of Retractable Technologies, Inc. v. OMI (Occupational & Medical Innovations Limited, an Australian company).

6 Mar 2010

Peptimmune granted US patent for PI-2301 peptide copolymer in treatment of multiple sclerosis

Peptimmune, Inc. a privately held biotechnology company, announced today the grant of US Patent Number 7,655,221 (the '221 patent) which protects the target product profile for its PI-2301 peptide copolymer for the treatment of multiple sclerosis, and other autoimmune diseases.

6 Mar 2010

Researchers assess clinical and cost impacts of PPI utilization in hospitalized patients

Proton pump inhibitors (PPIs) are the most effective agents for treating acid related gastrointestinal (GI) disorders. The utilization of intravenous (IV) formulations of PPIs has dramatically increased in health care institutions for inappropriate indications, route of administration and length of treatment. This is associated with an increased cost burden, increased risk of IV related infections, and utilization of hospital resources.

6 Mar 2010

Humanetics' BIO 300 medical radiation countermeasure drug candidate issued U.S. patent

In an announcement today, Humanetics Corporation reported that its BIO 300 medical radiation countermeasure drug candidate has been issued a U.S. patent. The patent is assigned to the United States of America with Humanetics as the designated licensee.

5 Mar 2010

German Federal Patent Court to nullify CryoLife's Kowanko patent

The German Federal Patent Court in Munich has indicated their intention to nullify the German patent DE 693 31 011 (German Kowanko patent) assigned to CryoLife, Inc. of Kennesaw, GA. This is the German part of the European Patent 0 650 512 and is key intellectual property relating to the BioGlue® Surgical Adhesive which is marketed worldwide by CryoLife, Inc.

5 Mar 2010

Advaxis' Listeria based fusion protein granted U.S. patent

The US Patent and Trademark Office (USPTO) has issued Advaxis, Inc.,, the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, patent #7662396 titled “Compositions and Methods for Enhancing the Immunogenicity of Antigens” for the use of fusion proteins that have been found to be effective in numerous models for the treatment of cancer in the presence of immune tolerance.

5 Mar 2010

Kyto Biopharma signs licensing agreement with RFSUNY, gains patent rights to Transcobalamin Receptor

Kyto Biopharma Inc., is pleased to announce that it has signed a licensing agreement with the Research Foundation of the State University of New York. The licensing agreement grants Kyto patent rights to the Transcobalamin (Vitamin B12) Receptor and to an additional broad group of other patents which are critical to Kyto’s research and development strategy for the treatment of cancer.

5 Mar 2010

Alnylam Pharmaceuticals asks Court to dismiss MIT from any claims for monetary damages in ongoing litigation

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the company and Max Planck have asked the Court to dismiss the Massachusetts Institute of Technology from any claims for monetary damages in the ongoing litigation related to the Tuschl I patent series.

4 Mar 2010

CRH Medical receives Japanese Notice of Allowance for CRH O'Regan System

CRH Medical Corporation announced today that the Japanese Patent Office has provided a Notice of Allowance for a patent application filed by the Company and related to CRH Medical's hemorrhoid technology, the CRH O'Regan System(TM). The Japanese patent is expected to be issued in the next several weeks and will provide additional protection to the Company's proprietary technology platform.

3 Mar 2010

VUCCC files for patent protection: New treatment regimen for Type 1 insulin-dependent diabetes

VUCCC P/L is pleased to announce that it has filed for patent protection of its ground breaking new treatment regimen for Type 1 'insulin-dependent' diabetes, through the European Patent Office.

3 Mar 2010

YM BioSciences files Form 6K regarding certain nimotuzumab US patents

YM BioSciences Inc., announces that it filed a Form 6K describing that certain US patents for nimotuzumab licensed to YM's majority-owned Canadian subsidiary , CIMYM BioSciences Inc., have become subject to a lien in the United States, pursuant to a court order, to a third party.

3 Mar 2010

Acuo Technologies granted patent covering technology implemented in DSG software suite

Acuo Technologies, the market leading Vendor Neutral Archive supplier, was granted US patent number 7,640,171 by the USPTO which covers technology implemented in its DICOM Services Grid™ software suite.

3 Mar 2010

Instacare announces filing of patent application for MD@Hand technologies

Instacare Corp., a leading provider of prescription drugs, home testing products for the chronically ill, a leading fulfillment provider of direct to patient diabetes programs, and a leading developer of revolutionary cell phone centric e-health products and technologies, today announced that on Friday, February 26, 2010, the Company filed a Provisional Patent Application to secure its MD@Hand technologies.

3 Mar 2010

ImmunoCellular Therapeutics receives Notice of Allowance on ICT-69 monoclonal antibody

ImmunoCellular Therapeutics, Ltd., a biotechnology company that is developing immune based therapies for the treatment of various forms of cancer, announced today it received a Notice of Allowance on monoclonal antibody ICT-69 which targets multiple myeloma and ovarian cancers. The antibody has demonstrated high specificity to these cancers by targeting a novel cell surface antigen.

2 Mar 2010

Amedica awarded U.S patent for advance bearing technology

Amedica Corporation, a spinal and orthopaedic implant and instrument company focused on unique silicon nitride (SiN) ceramic technologies, announced today that it has been granted United States Patent No. 7,666,229 covering its novel ceramic-on-ceramic bearings for articulating joints used for total joint replacement and spinal disc applications.

2 Mar 2010

Generic Hyzaar and Cozaar litigation: Court of Appeals rules in favor of Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. announced today that the U.S. Court of Appeals for the District of Columbia Circuit has ruled in Teva’s favor by overturning a July 31, 2009, district court decision which held that Teva forfeited 180-day marketing exclusivity for its generic versions of Merck's antihypertensive agents Hyzaar® (hydrochlorothiazide; losartan potassium) and Cozaar® (losartan potassium).

2 Mar 2010

Biomoda receives U.S patent for cancer and pre-cancer cell based diagnostic assay

Biomoda, Inc. (www.biomoda.com) was today awarded U.S. patent 7,670,799, entitled, "Composition and Method for Making 5, 10, 15, 20- Tetrakis (Carboxyphenyl) Porphine (TCPP)" directed to Biomoda's proprietary TCPP formulation for cancer and pre-cancer cell identification and analysis and a method of making the TCPP formulation.

2 Mar 2010

Medical Patent News

VIVUS granted three additional patents for Qnexa

USPTO issues non-final Actions Closing Prosecution for 6,833,252 and 7,214,536 patents

Sandata Technologies, Infocrossing reach agreement over patent infringement lawsuit

Retractable Technologies v. OMI litigation: Court delivers final judgment and permanent injunction

Peptimmune granted US patent for PI-2301 peptide copolymer in treatment of multiple sclerosis

Researchers assess clinical and cost impacts of PPI utilization in hospitalized patients

Humanetics' BIO 300 medical radiation countermeasure drug candidate issued U.S. patent

German Federal Patent Court to nullify CryoLife's Kowanko patent

Advaxis' Listeria based fusion protein granted U.S. patent

Kyto Biopharma signs licensing agreement with RFSUNY, gains patent rights to Transcobalamin Receptor

Alnylam Pharmaceuticals asks Court to dismiss MIT from any claims for monetary damages in ongoing litigation

CRH Medical receives Japanese Notice of Allowance for CRH O'Regan System

VUCCC files for patent protection: New treatment regimen for Type 1 insulin-dependent diabetes

YM BioSciences files Form 6K regarding certain nimotuzumab US patents

Acuo Technologies granted patent covering technology implemented in DSG software suite

Instacare announces filing of patent application for MD@Hand technologies

ImmunoCellular Therapeutics receives Notice of Allowance on ICT-69 monoclonal antibody

Amedica awarded U.S patent for advance bearing technology

Generic Hyzaar and Cozaar litigation: Court of Appeals rules in favor of Teva Pharmaceutical Industries

Biomoda receives U.S patent for cancer and pre-cancer cell based diagnostic assay

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News